Board of DirectorsMr Iain Ross Chairman,Non-Executive DirectorMr Bryce Carmine Non-Executive DirectorMr Steven Coffey Non-Executive DirectorDr James Garner Chief Executive Officer, Managing DirectorThree International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000ASX RELEASE10 December2020KAZIA TO COLLABORATE WITH PACIFIC PEDIATRIC NEURO-ONCOLOGY CONSORTIUM (PNOC) FOR NEW PAXALISIB COMBINATION STUDY IN DIPGSydney,10 December2020–Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has executed a Letter of Intentwith the Pacific Pediatric Neuro-Oncology Consortium (PNOC) to launch a clinical trial of multiple therapies, including Kazia’s investigational new drug, paxalisib (formerly GDC-0084), in diffuse midline gliomas including diffuse intrinsic pontine glioma (DIPG). The new clinical trial, PNOC022, will employ an adaptive trial design to test several therapies in different combinations and in different subsets of patients. In addition to paxalisib, the other therapies involved will initially include ONC201, manufactured by Oncoceutics, Inc, and panobinostat, manufactured by SecuraBio, Inc. The study is expected to open initially in the United States and will then expand to other countries during CY2021. Key Points•PNOC022 uses cutting edge clinical trial design to efficiently and rapidly evaluate combination therapies in DIPG, under the leadership of world experts in the field•Lead investigator is Professor Sabine Mueller, a leading paediatric neuro-oncologist and co-founder of PNOC•Study is guided by Australian research at University of Newcastle, under leadership of Associate Professor Matt Dun, who serves as a scientific advisor•Combination approachbuilds on recent positive data from St Jude SJPI3K study (NCT03696355) with paxalisib as single agentin DIPG, and brings together several of the most promising candidates in the global pipeline for DIPG•Kazia will provide paxalisib investigational product; study is fullyfunded by PNOC Kazia CEO, Dr James Garner, commented, “DIPG and diffuse midline gliomas have emerged as an exciting second front in the development of paxalisib as a brain cancer therapy. Work by Dr Chris Tinkle and colleagues at St Jude Children’s Research Hospital has taught us a great deal about how to use this drug in a paediatric population. In parallel, extensive laboratory research by Associate Professor Matt Dun and colleagues has generated a rich and comprehensive data set to inform combination use.
